Indegene launched Cortex, a fit-for-purpose Generative AI (GenAI) platform for life science industry

This innovative platform is strategically essential to developing and scaling high-value life sciences use cases, such as streamlining the content supply chain, making medical writing more effective and efficient, and accelerating medical legal regulatory (MLR) reviews. Its knowledge engineering interface codifies Indegene’s 25+ years of subject matter expertise into advanced knowledge graphs using a domain-friendly interface.Moreover, its fit-for-purpose agents can be configured with any preferred Large Language Model (LLM)

Revenue zoomed 6.73% to ₹2047.7 crore for the quarter ended December 2024, compared to ₹1918.6 crore during the corresponding quarter last year.

A comparatively good net profit growth of 37.28% to ₹128.5 crore was reported for the quarter ended December 2024, compared to ₹93.6crore of the mes from LLM-based million with substantially faster turnaround times and better ROI at lower risk, relative to industry-agnostic platforms.

This GenAI platform’s embedded domain knowledge graphs capture nuances and details of life sciences’ processes and tasks and benefit from continuous improvement.

Indegene provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical devices companies. These services assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and product sales and marketing.